EP1945669A4 - Chimeric antibodies with new world primate regions - Google Patents

Chimeric antibodies with new world primate regions

Info

Publication number
EP1945669A4
EP1945669A4 EP06774813A EP06774813A EP1945669A4 EP 1945669 A4 EP1945669 A4 EP 1945669A4 EP 06774813 A EP06774813 A EP 06774813A EP 06774813 A EP06774813 A EP 06774813A EP 1945669 A4 EP1945669 A4 EP 1945669A4
Authority
EP
European Patent Office
Prior art keywords
regions
chimeric antibodies
new world
world primate
primate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06774813A
Other languages
German (de)
French (fr)
Other versions
EP1945669A1 (en
Inventor
Philip Anthony Jennings
Anthony Gerard Doyle
Adam William Clarke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals Australia Pty Ltd
Original Assignee
Arana Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005904406A external-priority patent/AU2005904406A0/en
Application filed by Arana Therapeutics Ltd filed Critical Arana Therapeutics Ltd
Publication of EP1945669A1 publication Critical patent/EP1945669A1/en
Publication of EP1945669A4 publication Critical patent/EP1945669A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP06774813A 2005-08-15 2006-08-15 Chimeric antibodies with new world primate regions Withdrawn EP1945669A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2005904406A AU2005904406A0 (en) 2005-08-15 New World Antibodies
PCT/AU2006/001166 WO2007019621A1 (en) 2005-08-15 2006-08-15 Chimeric antibodies with new world primate regions

Publications (2)

Publication Number Publication Date
EP1945669A1 EP1945669A1 (en) 2008-07-23
EP1945669A4 true EP1945669A4 (en) 2009-07-22

Family

ID=37757238

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06774813A Withdrawn EP1945669A4 (en) 2005-08-15 2006-08-15 Chimeric antibodies with new world primate regions

Country Status (13)

Country Link
EP (1) EP1945669A4 (en)
JP (1) JP2009504686A (en)
KR (1) KR20080068005A (en)
CN (2) CN101287762A (en)
AU (1) AU2006281981A1 (en)
BR (2) BRPI0614867A2 (en)
CA (1) CA2619245A1 (en)
MX (1) MX2008002161A (en)
NO (1) NO20080800L (en)
NZ (1) NZ565904A (en)
RU (1) RU2008110058A (en)
WO (1) WO2007019621A1 (en)
ZA (2) ZA200802247B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001015A (en) 2004-07-26 2007-04-12 Biogen Idec Inc Anti-cd154 antibodies.
AU2007211829C9 (en) 2006-02-01 2013-07-11 Cephalon Australia Pty Ltd Domain antibody construct
PL2125894T3 (en) * 2007-03-22 2019-08-30 Biogen Ma Inc. Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
EP2318436A4 (en) * 2008-08-14 2012-12-19 Cephalon Australia Pty Ltd Variant domain antibodies
RU2519862C2 (en) * 2010-08-06 2014-06-20 Олег Ильич Эпштейн Complex medication and method of prevention and treatment of infectious viral diseases
RU2505312C2 (en) * 2010-08-06 2014-01-27 Олег Ильич Эпштейн Combined therapeutic agent for treating various types of influenza
RU2535033C2 (en) * 2010-08-06 2014-12-10 Олег Ильич Эпштейн Therapeutic agent and method for prevention of hiv infection and treatment of hiv-caused or hiv-associated diseases, including aids
RU2535034C2 (en) * 2010-08-06 2014-12-10 Олег Ильич Эпштейн Medication and method of preventing hiv infection, prevention and treatment of hiv-induced or hiv-associated diseases, including aids
RU2502521C2 (en) * 2010-08-06 2013-12-27 Олег Ильич Эпштейн Combined drug for treating bacterial infections and method of treating bacterial infections
RU2516931C2 (en) * 2010-08-06 2014-05-20 Олег Ильич Эпштейн Method and composition for preventing hiv infection, preventing and treating hiv-caused or hiv-associated diseases, including aids
RU2577299C2 (en) * 2011-07-04 2016-03-10 Олег Ильич Эпштейн Method for treating infectious diseases and complex medication for treatment of infectious diseases
RU2521392C2 (en) * 2010-08-06 2014-06-27 Олег Ильич Эпштейн Combined drug for treating viral infections and method of treating viral infections
RU2517085C2 (en) * 2010-08-06 2014-05-27 Олег Ильич Эпштейн Complex medication and method of preventing hiv infection, prevention and treatment of hiv-induced and hiv-associated diseases, including aids
RU2579262C1 (en) * 2014-10-02 2016-04-10 Мапикс Эс.Эй.Ар.Эл. Medicinal agent for treating infectious diseases
CL2015002152A1 (en) * 2015-07-31 2016-06-03 Pontificia Universidad Católica De Chile Monoclonal antibodies specific for the human syncytial respiratory virus (vrsh) antigen, produced and secreted by cellular hybridomas, useful for the detection and diagnosis of infection caused by vrsh

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002108A1 (en) * 1991-07-25 1993-02-04 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
WO2002033042A2 (en) * 2000-10-17 2002-04-25 The Regents Of The University Of California Recombinant antibody fragments as autoantibody antagonists
US20030143682A1 (en) * 2000-11-07 2003-07-31 Nicolaides Nicholas C. Antibodies and methods for generating genetically altered antibodies with high affinity
WO2004003019A2 (en) * 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007534305A (en) * 2003-11-07 2007-11-29 アムジェン インコーポレイテッド Monkey immunoglobulin sequence

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993002108A1 (en) * 1991-07-25 1993-02-04 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
WO2002033042A2 (en) * 2000-10-17 2002-04-25 The Regents Of The University Of California Recombinant antibody fragments as autoantibody antagonists
US20030143682A1 (en) * 2000-11-07 2003-07-31 Nicolaides Nicholas C. Antibodies and methods for generating genetically altered antibodies with high affinity
WO2004003019A2 (en) * 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FOOTE J ET AL: "Antibody framework residues affecting the conformation of the hypervariable loops", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 224, no. 2, 20 March 1992 (1992-03-20), pages 487 - 499, XP024011188, ISSN: 0022-2836, [retrieved on 19920320] *
HOLT L J ET AL: "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 11, 1 November 2003 (2003-11-01), pages 484 - 490, XP004467495, ISSN: 0167-7799 *
REITER Y ET AL: "An antibody single-domain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 290, no. 3, 1 January 1999 (1999-01-01), pages 685 - 698, XP004461990, ISSN: 0022-2836 *
See also references of WO2007019621A1 *
SPEIDEL M T ET AL: "Detection of human and marmoset immunoglobulin heavy chain by a polyclonal antiserum to a marmoset immunoglobulin-related T cell product", EXPERIMENTAL AND CLINICAL IMMUNOGENETICS, S.KARGER, BASEL, CH, vol. 6, no. 4, 1 January 1989 (1989-01-01), pages 245 - 250, XP009116561, ISSN: 0254-9670 *
VON BUDINGEN HANS-CHRISTIAN ET AL: "Characterization of the expressed immunoglobulin IGHV repertoire in the New World marmoset Callithrix jacchus", IMMUNOGENETICS, vol. 53, no. 7, September 2001 (2001-09-01), pages 557 - 563, XP002527012, ISSN: 0093-7711 *

Also Published As

Publication number Publication date
AU2006281981A1 (en) 2007-02-22
EP1945669A1 (en) 2008-07-23
ZA200802246B (en) 2009-09-30
RU2008110058A (en) 2009-09-27
CN101287763A (en) 2008-10-15
JP2009504686A (en) 2009-02-05
WO2007019621A1 (en) 2007-02-22
CN101287762A (en) 2008-10-15
KR20080068005A (en) 2008-07-22
BRPI0614867A2 (en) 2012-01-31
MX2008002161A (en) 2008-04-22
NZ565904A (en) 2012-02-24
ZA200802247B (en) 2009-08-26
NO20080800L (en) 2008-05-09
CA2619245A1 (en) 2007-02-22
BRPI0614430A2 (en) 2011-03-29

Similar Documents

Publication Publication Date Title
ZA200802247B (en) Chimeric antibodies with new world primate regions
EP1945668A4 (en) Engineered antibodies with new world primate framework regions
EP1969009A4 (en) Chimeric antibodies with part new world primate binding regions
HK1218126A1 (en) Anti-ilt7 antibody ilt7
EP1874927A4 (en) Improved cellulases
IL187106A (en) Sclerostin-binding antibody
IL190472A0 (en) Anti-glypican-3 antibody
AP2007004243A0 (en) Antibodies to myostatin
EP1854410A4 (en) Biosensor coupled with needle
GB0503546D0 (en) Antibody
GB0517487D0 (en) Antibodies
EP1896047A4 (en) Anti-gfralpha3 antibodies
GB0505489D0 (en) Antibodies
GB0512278D0 (en) Antibodies
GB0505054D0 (en) Antibodies
GB0519883D0 (en) Antibodies
GB0509392D0 (en) Improvements to the controllable petrol can
GB0616587D0 (en) Intelligent buggy
GB0521710D0 (en) Fork extension
GB0606276D0 (en) Antibodies
GB0607376D0 (en) Antibodies
GB0503580D0 (en) Travel phone
GB0500400D0 (en) Antibody
GB0501709D0 (en) H/h/t
GB0510408D0 (en) Harware interface

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080317

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/46 20060101ALI20090528BHEP

Ipc: A61K 39/395 20060101ALI20090528BHEP

Ipc: C07K 16/18 20060101AFI20070420BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090618

17Q First examination report despatched

Effective date: 20091006

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CEPHALON AUSTRALIA PTY LTD

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130301